Menu Search
Equities

Eurofins Scientific SE

ERF:PAR

Eurofins Scientific SE

Actions
Health CareMedical Equipment and Services
  • Price (EUR)46.36
  • Today's Change0.50 / 1.09%
  • Shares traded419.87k
  • 1 Year change-10.33%
  • Beta0.5029
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform4
Hold6
Sell3
Strong Sell1

Share price forecast in EUR

The 15 analysts offering 12 month price targets for Eurofins Scientific SE have a median target of 55.00, with a high estimate of 89.00 and a low estimate of 42.00. The median estimate represents a 18.64% increase from the last price of 46.36.
High92.0%89.00
Med18.6%55.00
Low-9.4%42.00

Dividends in EUR

In 2023, Eurofins Scientific SE reported a dividend of 0.50 EUR, which represents a 50.00% decrease from last year. The 15 analysts covering the company expect dividends of 0.63 EUR for the upcoming fiscal year, an increase of 25.80%.
Div growth (TTM)-50.00%
More ▼

Earnings history & estimates in EUR

Eurofins Scientific SE reported annual 2023 earnings of 2.64 per share on Feb 27, 2024.
Average growth rate+25.94%
More ▼

Revenue history & estimates in EUR

of 1.62bn. This bettered the 1.62bn consensus of the 2 analysts covering the company.
Average growth rate+0.08%
Eurofins Scientific SE had revenues for the full year 2023 of 6.51bn. This was 2.94% below the prior year's results.
Average growth rate+9.92%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.